关键数据
0.660今开
0.680最高
72.60K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.15%换手率
0.672昨收
0.650最低
38.09K成交额
亏损市盈率静
0.70市净率
0.00%股息率 TTM
-107.86%ROA
2.93252周最高
1.78量比
-32.01M净利润
46.84M总股本
-0.6984每股收益TTM
0.75Beta
-142.60%ROE
0.86452周最低
4.45%振幅
20.22%毛利率
30.45M总市值
-1.01回报/风险
3.86%风险率
操作建议
InspireMD Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名118/199位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价3.67。中期看,股价处于下降通道。近一个月,市场表现较差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
InspireMD Inc新闻
即将为您带来更多新闻,敬请期待。。。
收益预测
Zimmer Biomet Holdings Inc
ZBH
31
技术指标
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
InspireMD Inc简介
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
公司代码NSPR
公司InspireMD Inc
CEOSlosman (Marvin L)
网址https://www.inspiremd.com/en/
公司股东
常见问题
InspireMD Inc(NSPR)的当前股价是多少?
InspireMD Inc(NSPR)的当前股价是 0.65。
InspireMD Inc股票的52周最高点是多少?
InspireMD Inc股票的52周最高点是2.93。
InspireMD Inc股票的52周最低点是多少?
InspireMD Inc股票的52周最低点是0.86。
现在InspireMD Inc(NSPR)的股票是买入、持有还是卖出?
根据分析师评级,InspireMD Inc(NSPR)的总体评级为买入,目标价格为3.67。
InspireMD Inc(NSPR)股票的每股收益(EPS TTM)是多少
InspireMD Inc(NSPR)股票的每股收益(EPS TTM)是-0.76。